The ANA-HEp-2 (Antinuclear Antibody) test is a diagnostic tool used to detect the presence of autoantibodies that target antigens in the nucleus of cells. It is often used to diagnose and monitor autoimmune diseases such as Systemic Lupus Erythematosus (SLE), Sjögren’s syndrome, and rheumatoid arthritis.

• Method: Indirect Immunofluorescence (IIF) on HEp-2 cells (a human epithelial cell line).
• Purpose: Screens for autoantibodies that may indicate autoimmune disorders.
• Sample Type: Serum (blood sample from a vein).

Risk Assessment

• Low Risk: Negative ANA test. However, a negative result does not entirely rule out all autoimmune diseases.
• High Risk: Positive ANA test, especially at high titers (e.g., ≥1:160). Specific staining patterns (e.g., homogeneous, speckled, nucleolar) can indicate potential autoimmune conditions.

Normal Range

• Negative Result: ANA titer <1:40 or no fluorescent staining.
  • Indicates the absence of detectable autoantibodies.
• Positive Result: ANA titer ≥1:40 or a distinct staining pattern.

Interpretation

1. Negative ANA:

   • No significant autoantibodies detected.
   • Autoimmune disease is unlikely but not entirely excluded.

2. Positive ANA:

   • Presence of autoantibodies; further testing (e.g., specific antibody panels) required to identify the exact autoimmune disease.
   • Common conditions associated with a positive ANA:
     • Homogeneous pattern: Often linked to SLE or drug-induced lupus.
     • Speckled pattern: Associated with Sjögren's syndrome, mixed connective tissue disease.
     • Nucleolar pattern: Suggestive of systemic sclerosis.
     • Centromere pattern: Indicates CREST syndrome (a limited form of systemic sclerosis).

Sample Type

• Blood Serum: A venous blood sample is collected and centrifuged to separate the serum for analysis.